Being a leading cause of death in the health sector, cancer has claimed many lives. The puzzle behind its causative agent, cure and therapy has led to the contribution of several scientists, donors, physicians, therapists and researchers. Faced with the challenge to address these issues, organizations have merged to come up with treatment methods and therapies. Such is the input of Mikhail Blagosklonny, a research scientist. Being a specialist in biology and cancer treatment as well as therapies, Mikhail has been instrumental in the battle against cancer. Most of his works have revolutionary transformed the medical landscape.
Blagosklonny is a recognized oncology research scientist. His works extend to authoring more than 150 articles on cancer cell biology. Aside from that, Mikhail has been an assistant author for multiple book chapters as well as reviews based on the molecular composition of cancer cells and their behavior in healthy human cells. Mikhail has given detailed research insight on cancer cells including the cycle involved in apoptosis and autophagy. Through his widely cited insight, Mikhail has focused on the theory of aging through molecular study.
Towards this end, Mikhail was of the opinion that TOR Signaling, also known as target of rapamycin has a significant input in prolonging the life cell of the human body. This is because through TOR Signaling, there is a delay in autophagy and an increase in protein synthesis. Mikhail further stated that it is crucial for medical practitioners to understand these processes. This is because with detailed understanding, treatment becomes relatively easier. Additionally, the processes have a slowing effect on age-related diseases. According to Blagosklonny, too much rapamycin contribute to the inhibition of autophagy, leading to cancerous tumors. Mikhail is hopeful that these processes will be understood in detail with the aim of finding painless and reliable treatment options for terminal and age-related illnesses. To Mikhail, it is vital to invest in the understanding of these processes.
Blagosklonny’s input in the medical field extends beyond research works. As a scholar, he is recognized for the vast experience he harbors in research institutions. Mikhail’s experience extends to Roswell Institute of Research where he is a highly regarded professor of oncology. His appointment in 2009 was influenced by his experiences. He also landed an executive role at the Ordway Institute of Research where he served as a research scientist. In 2002, Mikhail Blagosklonny’s academic credentials supported his role as a lead specialist in experimental medicine. Blagosklonny was thence appointed as a medical associate professor for the New York Medical College.
Currently, Blagosklonny is a lead editor for Oncotarget. This is a peer-reviewed journal that focuses on sharing vital information concerning diseases and the proposed treatments. Through Oncotarget, Blagosklonny, Oncotarget addresses arising medical issues. These issues are then published on the journal. Depending on the demand, the articles can be printed for weekly use. Blagosklonny insists that as time moves, there are more discoveries made towards treating diseases. Mikhail has extensively invested in finding curative measures for cancer and diseases that are related to old age.